RESUMO
Background The ability to perceive sound is crucial for effective communication and environmental awareness. This study aimed to assess sensorineural hearing loss (SNHL) in patients with both diabetes mellitus (DM) and hypertension (HTN). Materials and methods A total of 120 participants of both genders were divided into three groups: Group I consisted of diabetic patients (n=40, 22 males and 18 females), Group II included hypertensive individuals (n=40, 16 males and 24 females), and Group III served as controls (n=40, 15 males and 25 females). General ear examinations, including otoscopy, were conducted. Hearing function and the degree, pattern, and configuration of hearing loss were assessed using general ear examinations and pure tone audiometry. Results Normal hearing was observed in 25% of Group I, 26% of Group II, and 85% of Group III. Mild hearing loss was evident in 75% of Group I, 50% of Group II, and 15% of Group III, while moderate hearing loss was observed in 24% of Group II. These differences were statistically significant (P < 0.05). Conclusion Diabetic and hypertensive individuals demonstrated a higher hearing loss prevalence than healthy controls.
RESUMO
Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, is a chronic inflammatory condition of the gastrointestinal tract. Recent research indicates a significant link between IBD and cardiovascular disease (CVD), the leading cause of global morbidity and mortality. This review examines the association between IBD and CVD, emphasizing the role of the gut microbiome in this relationship. IBD patients have a higher risk of cardiovascular events, such as coronary artery disease, heart failure, and cerebrovascular incidents, primarily due to chronic systemic inflammation, genetic factors, and gut microbiota imbalance (dysbiosis). Dysbiosis in IBD increases intestinal permeability, allowing bacterial products to enter the bloodstream, which promotes inflammation and endothelial dysfunction, contributing to CVD. Understanding the gut microbiome's role in IBD and CVD suggests new therapeutic interventions. Modulating the microbiome through diet, probiotics, and fecal microbiota transplantation (FMT) are promising research avenues. These interventions aim to restore a healthy gut microbiota balance, potentially reducing inflammation and improving cardiovascular outcomes. Additionally, the review emphasizes the importance of regular cardiovascular risk assessments and personalized preventive measures in managing IBD patients. Such measures include routine monitoring of cardiovascular health, tailored lifestyle modifications, and early intervention strategies to mitigate cardiovascular risk. By integrating current knowledge, this review aims to improve understanding and management of the interconnected pathophysiology of IBD and CVD. This approach will ultimately enhance patient outcomes and provide a foundation for future research and clinical practice guidelines in this area.
RESUMO
Drug-induced acute pancreatitis is a potentially ignored diagnosis that must be precisely valued. Drug-induced acute pancreatitis can be considered the third common cause of acute pancreatitis after ruling out alcohol and gallstones. Levofloxacin belongs to a class of fluoroquinolone antibiotics used for treating various infections. Besides photosensitivity and liver toxicity, levofloxacin can induce acute pancreatitis, although rarely described. We highlight a case of acute pancreatitis in a female induced by levofloxacin. She presented with typical signs and symptoms of acute pancreatitis and had been taking levofloxacin for urinary tract infections for the last 3 days. After ruling out all other possible causes, her clinical picture, laboratory results, and imaging findings confirmed acute pancreatitis induced by levofloxacin.